Skip to main content

Table 1 Baseline characteristics of the sample

From: Sexuality and cancer in adolescents and young adults - a comparison between reproductive cancer patients and patients with non-reproductive cancer

 

Total (N = 577)

Women n = 424 (73.5%)

Men n = 153 (26.5%)

All

NRC n = 223

RC n = 201

df

p

All

NRC n = 103

RC n = 50

df

p

Age at diagnosis - Mean (SD)

29.30 (6.09)

29.09 (6.00)

27.72 (5.99)

32.32 (5.02)

422

≤.001***

27.76 (6.09)

27.26 (6.24)

28.78 (5.68)

151

.143

Months since diagnosis - Mean (SD)

11.89 (7.99)

11.78 (7.60)

11.85 (8.48)

11.69 (6.51)

406

.829

12.22 (9.01)

13.17 (8.97)

10.26 (8.87)

145

.061

 

N (%)

n (%)

n (%)

n (%)

  

n (%)

n (%)

n (%)

  

Partnershipa

391 (67.8)

308 (73.2)

154 (69.1)

154 (77.8)

1

.044*

83 (54.2)

54 (52.4)

29 (58.0)

1

.516

Children

184 (31.9)

152 (35.8)

68 (30.5)

84 (41.8)

1

.015*

32 (21.1)

24 (23.5)

8 (16.0)

1

.285

Highest educational degreeb

    

5

.509

   

5

 

 No educational degree

6 (1.0)

3 (0.7)

3 (1.3)

0

  

3 (2.0)

3 (3.0)

0

  

 Basic educational degree (< 10 years)

37 (6.5)

23 (5.5)

13 (5.8)

10 (5.2)

  

14 (9.2)

9 (8.8)

5 (10.0)

  

 Secondary educational degree (10 years)

90 (33.2)

128 (32.8)

74 (33.2)

64 (32.2)

  

52 (34.2)

34 (33.3)

18 (36.0)

  

 High school degree (> 10 years)

340 (59.3)

257 (61.1)

133 (59.6)

124 (62.6)

  

83 (54.5)

56 (54.9)

27 (54.0)

 

n/a

Housing/living conditionsc

    

3

≤.001***

   

3

.200

 Single

131 (22.7)

95 (23.6)

49 (23.0)

46 (12.2)

  

36 (24)

20 (19.8)

16 (32.7)

  

 Living with partner

298 (51.6)

238 (59.1)

110 (51.6)

128 (67.4)

  

60 (40)

41 (40.6)

19 (38.8)

  

 Living in parental household

92 (16.6)

51 (12.7)

40 (18.8)

11 (5.8)

  

41 (27.3)

32 (31.7)

9 (18.4)

  

 Shared community

32 (5.8)

19 (4.7)

14 (6.6)

5 (2.6)

  

13 (8.7)

8 (7.9)

5 (10.2)

 

0

Reproductive Cancer [C50-C57, C62]

251 (43.5)

201 (47.4)

   

n/a

50 (32.7)

    

Non-Reproductive Cancer [All other C]

326 (56.5)

223 (52.6)

   

103 (67.3)

   

n/a

Cancer diagnosis

     

n/a

    

n/a

 [C50] Breast

150 (26.0)

150 (35.4)

   

0

   

 [C81] Hodgkin’s Lymphoma

99 (17.2)

66 (15.6)

   

33 (21.7)

   

 [C51-C57] Gynecological

51 (8.8)

51 (12.0)

   

0

   

 [C62] Testicular

50 (8.7)

0

   

50 (32.7)

   

 [C82-C90] Non-Hodgkin’s Lymphoma

42 (7.3)

22 (5.2)

   

20 (13.2)

   

 Others

41 (7.1)

24 (5.7)

   

17 (11.1)

   

 [C91-C95] Haematological

38 (6.6)

20 (4.7)

   

16 (10.5)

   

 [C73] Thyroid

32 (5.5)

30 (7.1)

   

2 (1.3)

   

 [C15-C26] Gastrointestinal

29 (5.0)

21 (5.0)

   

8 (5.2)

   

 [C40-C41, C46-C49] Sarcoma

26 (4.5)

20 (4.7)

   

6 (3.9)

   

 [C43] Melanoma

19 (3.3)

18 (4.2)

   

1 (0.7)

   

Therapies (multiple answers possible)d

 Chemotherapye

443 (76.8)

310 (73.1)

152 (68.2)

158 (78.6)

2

.015*

133 (86.9)

91 (88.5)

42 (84)

2

.454

 Surgery

427 (74.0)

325 (76.6)

139 (62.3)

186 (92.5)

2

≤.001***

102 (66.7)

54 (52.4)

48 (96)

2

≤.001***

 Radio and nuclear therapye

264 (45.8)

207 (48.8)

92 (41.3)

115 (57.2)

2

≤.001***

57 (37.3)

56 (54.4)

1 (2)

2

≤.001***

 Stem Cell/bone marrow transplantation

33 (5.7)

23 (5.5)

21 (9.4)

2 (1.0)

2

≤.001***

10 (6.6)

9 (8.7)

1 (2)

2

.114

  1. Males and females are listed separately and further broken down into groups of RCs and NRCs. t-tests and χ2 tests were performed between NRCs and RCs for each gender
  2. Missing: a3 (0.5%); b4 (0.7%); c24 (4.2%); dDue to further validation there are deviations to the baseline medical therapies published in the study protocol [44]; eincluding Radio-Chemotherpy; n/a not applicable